Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
| Ano de defesa: | 2008 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | |
| Tipo de documento: | Dissertação |
| Tipo de acesso: | Acesso aberto |
| dARK ID: | ark:/26339/0013000002w12 |
| Idioma: | por |
| Instituição de defesa: |
Universidade Federal de Santa Maria
Brasil Farmácia UFSM Programa de Pós-Graduação em Ciências Farmacêuticas Centro de Ciências da Saúde |
| Programa de Pós-Graduação: |
Não Informado pela instituição
|
| Departamento: |
Não Informado pela instituição
|
| País: |
Não Informado pela instituição
|
| Palavras-chave em Português: | |
| Link de acesso: | http://repositorio.ufsm.br/handle/1/27362 |
Resumo: | The approval of the protocol M-38A by Clinical and Laboratory Standards Institute (CLSI), which established standardized procedures for the evaluation of the in vitro susceptibility of moulds, has expanded the inherent knowledge about the fungi susceptibility against the most commonly used antifungal drugs. In this study, fortyone Sporothrix schenckii clinical isolates from both animals and humans have had their in vitro susceptibility against miconazole, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, caspofungin and amphotericin B tested, by the microdilution method, established by the protocol M-38A. The isolates have shown the highest in vitro susceptibility to terbinafine (MIC90= 0.25 μg/mL) and the lowest to fluconazole (MIC90= 128 μg/mL). Thirty-five isolates (85.37%) have shown MIC < 1.0 μg/mL against itraconazole while three isolates have shown MIC > 16 μg/mL. Regarding voriconazole (MIC90= 16 μg/mL) and caspofungin (MIC90= 32 μg/mL), the MIC values found demonstrate a profile of low susceptibility of the tested isolates. The MIC values found for amphotericin B (MIC90 = 1 μg/mL), have shown a profile of sensibility of the isolates evaluated in this study. In the evaluation of disseminated sporotrichosis in murine models, the treatment efficacy with itraconazole, voriconazole and amphotericin B were determined and compared. The antifungal therapy with amphotericin B have shown higher effectiveness compared to the control group (p<0.001) and to the other treatments (p<0.05). Through the subdivision of the mice’s groups by gender, could be observed a variation in the extension of Sporothrix schenckii disseminated infection, with males showing more damaged organs (p<0.05). |
| id |
UFSM_6cb58fd06b0ebc93d279f07a93879405 |
|---|---|
| oai_identifier_str |
oai:repositorio.ufsm.br:1/27362 |
| network_acronym_str |
UFSM |
| network_name_str |
Manancial - Repositório Digital da UFSM |
| repository_id_str |
|
| spelling |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murinoIn vitro susceptibility of Sporothrix schenckii and evaluation of antifungal therapy in a murine model of systemic sporotrichosisSporothrix schenckiiAntifúngicosSuscetibilidadeIn vitroIn vivoAntifungalSusceptibilityCNPQ::CIENCIAS DA SAUDE::FARMACIAThe approval of the protocol M-38A by Clinical and Laboratory Standards Institute (CLSI), which established standardized procedures for the evaluation of the in vitro susceptibility of moulds, has expanded the inherent knowledge about the fungi susceptibility against the most commonly used antifungal drugs. In this study, fortyone Sporothrix schenckii clinical isolates from both animals and humans have had their in vitro susceptibility against miconazole, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, caspofungin and amphotericin B tested, by the microdilution method, established by the protocol M-38A. The isolates have shown the highest in vitro susceptibility to terbinafine (MIC90= 0.25 μg/mL) and the lowest to fluconazole (MIC90= 128 μg/mL). Thirty-five isolates (85.37%) have shown MIC < 1.0 μg/mL against itraconazole while three isolates have shown MIC > 16 μg/mL. Regarding voriconazole (MIC90= 16 μg/mL) and caspofungin (MIC90= 32 μg/mL), the MIC values found demonstrate a profile of low susceptibility of the tested isolates. The MIC values found for amphotericin B (MIC90 = 1 μg/mL), have shown a profile of sensibility of the isolates evaluated in this study. In the evaluation of disseminated sporotrichosis in murine models, the treatment efficacy with itraconazole, voriconazole and amphotericin B were determined and compared. The antifungal therapy with amphotericin B have shown higher effectiveness compared to the control group (p<0.001) and to the other treatments (p<0.05). Through the subdivision of the mice’s groups by gender, could be observed a variation in the extension of Sporothrix schenckii disseminated infection, with males showing more damaged organs (p<0.05).A aprovação do protocolo M38-A pelo Clinical and Laboratory Standards Institute (CLSI), que estabelece normas padronizadas para avaliação de suscetibilidade in vitro de fungos filamentosos, tem expandido o conhecimento inerente aos aspectos de suscetibilidade destes fungos frente aos antifúngicos convencionalmente utilizados na prática clínica. Neste estudo, quarenta e um isolados clínicos de Sporothrix schenckii, oriundos de humanos e animais, foram avaliados quanto à suscetibilidade in vitro frente ao miconazol, cetoconazol, itraconazol, fluconazol, voriconazol, terbinafina, caspofungina e anfotericina B. Utilizou-se a metodologia de microdiluição em placa estabelecida pelo protocolo M38-A . Os isolados demonstraram maior suscetibilidade in vitro frente à terbinafina (CIM90= 0,25 μg/mL) e menor suscetibilidade ao fluconazol (CIM90= 128 μg/mL). Trinta e cinco isolados (85,37%) apresentaram CIM < 1,0 μg/mL frente ao itraconazol; em três isolados evidenciou-se CIM > 16 μg/mL. Quanto ao voriconazol (CIM90= 16 μg/mL) e a caspofungina (CIM90= 32 μg/mL), os valores de CIM encontrados demonstram um perfil de reduzida suscetibilidade dos isolados testados. As CIMs determinadas frente à anfotericina B (CIM90 = 1 μg/mL) puderam evidenciar um perfil de sensibilidade dos isolados avaliados neste estudo. Na avaliação da esporotricose disseminada em modelo murino, a eficácia de tratamento com itraconazol, voriconazol e anfotericina foram determinadas e comparadas. A antifungicoterapia com anfotericina B evidenciou maior efetividade em relação ao grupo controle (p<0,001) e aos demais tratamentos (p<0,05). Através da subdivisão dos grupos de camundongos por sexo, pôde ser observada uma variação na extensão da infecção disseminada por Sporothrix schenckii com maior comprometimento das vísceras dos machos (p<0,05).Universidade Federal de Santa MariaBrasilFarmáciaUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasCentro de Ciências da SaúdeAlves, Sydney Hartzhttp://lattes.cnpq.br/0330782478769631Santurio, Jânio MoraisAthayde, Margareth LindeLopes, Paulo Guilherme Markus2022-12-15T16:53:46Z2022-12-15T16:53:46Z2008-03-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/27362ark:/26339/0013000002w12porAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-12-15T16:53:46Zoai:repositorio.ufsm.br:1/27362Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/PUBhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.bropendoar:2022-12-15T16:53:46Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false |
| dc.title.none.fl_str_mv |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino In vitro susceptibility of Sporothrix schenckii and evaluation of antifungal therapy in a murine model of systemic sporotrichosis |
| title |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino |
| spellingShingle |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino Lopes, Paulo Guilherme Markus Sporothrix schenckii Antifúngicos Suscetibilidade In vitro In vivo Antifungal Susceptibility CNPQ::CIENCIAS DA SAUDE::FARMACIA |
| title_short |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino |
| title_full |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino |
| title_fullStr |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino |
| title_full_unstemmed |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino |
| title_sort |
Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino |
| author |
Lopes, Paulo Guilherme Markus |
| author_facet |
Lopes, Paulo Guilherme Markus |
| author_role |
author |
| dc.contributor.none.fl_str_mv |
Alves, Sydney Hartz http://lattes.cnpq.br/0330782478769631 Santurio, Jânio Morais Athayde, Margareth Linde |
| dc.contributor.author.fl_str_mv |
Lopes, Paulo Guilherme Markus |
| dc.subject.por.fl_str_mv |
Sporothrix schenckii Antifúngicos Suscetibilidade In vitro In vivo Antifungal Susceptibility CNPQ::CIENCIAS DA SAUDE::FARMACIA |
| topic |
Sporothrix schenckii Antifúngicos Suscetibilidade In vitro In vivo Antifungal Susceptibility CNPQ::CIENCIAS DA SAUDE::FARMACIA |
| description |
The approval of the protocol M-38A by Clinical and Laboratory Standards Institute (CLSI), which established standardized procedures for the evaluation of the in vitro susceptibility of moulds, has expanded the inherent knowledge about the fungi susceptibility against the most commonly used antifungal drugs. In this study, fortyone Sporothrix schenckii clinical isolates from both animals and humans have had their in vitro susceptibility against miconazole, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, caspofungin and amphotericin B tested, by the microdilution method, established by the protocol M-38A. The isolates have shown the highest in vitro susceptibility to terbinafine (MIC90= 0.25 μg/mL) and the lowest to fluconazole (MIC90= 128 μg/mL). Thirty-five isolates (85.37%) have shown MIC < 1.0 μg/mL against itraconazole while three isolates have shown MIC > 16 μg/mL. Regarding voriconazole (MIC90= 16 μg/mL) and caspofungin (MIC90= 32 μg/mL), the MIC values found demonstrate a profile of low susceptibility of the tested isolates. The MIC values found for amphotericin B (MIC90 = 1 μg/mL), have shown a profile of sensibility of the isolates evaluated in this study. In the evaluation of disseminated sporotrichosis in murine models, the treatment efficacy with itraconazole, voriconazole and amphotericin B were determined and compared. The antifungal therapy with amphotericin B have shown higher effectiveness compared to the control group (p<0.001) and to the other treatments (p<0.05). Through the subdivision of the mice’s groups by gender, could be observed a variation in the extension of Sporothrix schenckii disseminated infection, with males showing more damaged organs (p<0.05). |
| publishDate |
2008 |
| dc.date.none.fl_str_mv |
2008-03-19 2022-12-15T16:53:46Z 2022-12-15T16:53:46Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
| format |
masterThesis |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/27362 |
| dc.identifier.dark.fl_str_mv |
ark:/26339/0013000002w12 |
| url |
http://repositorio.ufsm.br/handle/1/27362 |
| identifier_str_mv |
ark:/26339/0013000002w12 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Brasil Farmácia UFSM Programa de Pós-Graduação em Ciências Farmacêuticas Centro de Ciências da Saúde |
| publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Brasil Farmácia UFSM Programa de Pós-Graduação em Ciências Farmacêuticas Centro de Ciências da Saúde |
| dc.source.none.fl_str_mv |
reponame:Manancial - Repositório Digital da UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
| instname_str |
Universidade Federal de Santa Maria (UFSM) |
| instacron_str |
UFSM |
| institution |
UFSM |
| reponame_str |
Manancial - Repositório Digital da UFSM |
| collection |
Manancial - Repositório Digital da UFSM |
| repository.name.fl_str_mv |
Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM) |
| repository.mail.fl_str_mv |
atendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.br |
| _version_ |
1847153337569378304 |